Skip to main content
    I

    Intellia Therapeutics Inc (NTLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.86
    +0.16 (+1.65%)

    Market Cap: $1.36B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Intellia Therapeutics Inc (NTLA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Intellia Therapeutics reported revenue of $67.67M for the fiscal year ended Dec 31, 2025, up 16.9% from the year before. That year, net income was -$412.69M with a net margin of -609.9%, operating cash flow was -$394.74M and free cash flow was -$395.87M. The quarter ended Sep 30, 2026 had revenue of $7.16M and net income of -$127.48M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $16.48M, a compound annual rate of 17.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$67.67M+16.9%100.0%-651.7%-609.9%
    Dec 2024$57.88M+59.6%100.0%-923.1%-896.8%
    Dec 2023$36.27M-30.4%100.0%-1420.5%-1326.5%
    Dec 2022$52.12M+57.7%100.0%-879.0%-909.8%
    Dec 2021$33.05M-43.0%100.0%-810.4%-810.5%
    Dec 2020$57.99M+34.5%100.0%-235.5%-231.5%
    Dec 2019$43.10M+41.6%100.0%-246.8%-230.9%
    Dec 2018$30.43M+16.5%100.0%-298.6%-280.4%
    Dec 2017$26.12M+58.5%100.0%-266.3%-258.6%
    Dec 2016$16.48MN/A100.0%-195.2%-192.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$67.67M$57.88M$36.27M$52.12M$33.05M$57.99M$43.10M$30.43M$26.12M$16.48M
    Gross profit$67.67M$57.88M$36.27M$52.12M$33.05M$57.99M$43.10M$30.43M$26.12M$16.48M
    Research and development$388.86M$466.31M$435.07M$419.98M$229.81M$150.41M$108.41M$89.11M$67.65M$31.84M
    Operating income-$440.99M-$534.26M-$515.29M-$458.16M-$267.85M-$136.58M-$106.37M-$90.87M-$69.56M-$32.16M
    Net income-$412.69M-$519.02M-$481.19M-$474.19M-$267.89M-$134.23M-$99.53M-$85.34M-$67.54M-$31.63M
    EBITDA-$430.50MN/AN/AN/A-$255.52M-$129.73M-$96.77M-$87.11M-$66.56M-$31.05M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$7.16M$7.66M$15.05M$23.02M$13.78M$14.24M$16.63M$12.87M$9.11M$6.96M$28.93M-$1.92M
    Gross profit$7.16M$7.66M$15.05M$23.02M$13.78M$14.24M$16.63M$12.87M$9.11M$6.96M$28.93M-$1.92M
    Operating income-$122.33M-$112.76M-$100.53M-$98.71M-$111.48M-$110.00M-$120.81M-$136.45M-$144.77M-$139.04M-$114.00M-$139.89M
    Net income-$127.48M-$106.63M-$96.23M-$95.79M-$101.32M-$101.25M-$114.33M-$128.90M-$135.71M-$146.97M-$107.44M-$132.16M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $26.48M by $128.98M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$842.13M$1.19B$1.30B$1.52B$1.29B$676.32M$334.28M$347.31M$376.24M$298.97M
    Current assets$527.71M$639.86M$998.33M$1.22B$769.30M$616.52M$289.48M$324.98M$354.83M$281.31M
    Cash and equivalents$155.46M$189.18M$226.75M$523.51M$123.41M$160.02M$57.23M$58.86M$340.68M$273.06M
    Total liabilities$170.73M$319.06M$250.81M$284.53M$254.22M$149.25M$64.40M$69.39M$75.64M$89.13M
    Short-term debt$26.48M$20.25M$18.60M$16.68M$9.11M$5.70M$5.75MN/AN/AN/A
    Shareholder equity$671.39M$871.96M$1.05B$1.24B$1.04B$527.07M$269.88M$277.92M$300.60M$209.84M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$902.56M$857.16M$758.78M$842.13M$925.27M$898.89M$986.16M$1.19B$1.17B$1.19B$1.26B$1.30B
    Total liabilities$289.47M$129.46M$137.84M$170.73M$176.85M$183.64M$206.24M$319.06M$210.74M$220.47M$223.45M$250.81M
    Cash and equivalents$156.10M$106.13M$134.70M$155.46M$193.39M$156.17M$126.88M$189.18M$120.50M$130.85M$171.98M$226.75M
    Shareholder equity$613.09M$727.71M$620.94M$671.39M$748.42M$715.25M$779.92M$871.96M$962.62M$971.06M$1.04B$1.05B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$394.74M-$348.88M-$394.09M-$333.29M-$225.03M-$49.91M-$103.24M-$61.26M-$65.28M$36.11M
    Capital expenditures$1.13M$5.78M$13.98M$13.56M$12.76M$3.58M$6.79M$6.36M$10.09M$6.17M
    Free cash flow-$395.87M-$354.66M-$408.07M-$346.85M-$237.79M-$53.50M-$110.03M-$67.61M-$75.37M$29.94M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/AN/AN/A$2.76M
    Investing cash flow$228.03M$125.57M-$31.35M$160.31M-$550.78M-$214.49M$25.18M-$260.78M-$10.09M-$6.17M
    Financing cash flow$131.49M$185.75M$130.32M$582.96M$736.69M$371.78M$76.43M$40.22M$142.98M$167.30M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$85.43M-$83.11M-$117.35M-$69.28M-$76.90M-$99.62M-$148.93M-$85.19M-$84.84M-$58.19M-$120.66M-$93.05M
    Capital expenditures$888.00K$1.81M$79.00K$126.00K$29.00K$239.00K$735.00K$981.00K$1.28M$1.01M$2.51M$1.52M
    Free cash flow-$86.32M-$84.92M-$117.42M-$69.41M-$76.93M-$99.86M-$149.66M-$86.18M-$86.12M-$59.20M-$123.17M-$94.57M
    Last 12 quarters

    Frequently Asked Questions About NTLA

    What is Intellia Therapeutics' annual revenue?

    Intellia Therapeutics reported revenue of $67.67M for the fiscal year ended Dec 31, 2025.

    How fast is Intellia Therapeutics' revenue growing?

    Revenue was up 16.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 9.1%.

    Is Intellia Therapeutics profitable?

    No. Intellia Therapeutics reported net income of -$412.69M for the fiscal year ended Dec 31, 2025, with a net margin of -609.9%.

    How much free cash flow does NTLA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$394.74M minus capital expenditures of $1.13M produced free cash flow of -$395.87M.

    How much debt does Intellia Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $26.48M and cash and equivalents of $155.46M.